ArticleJournal, genetic engineering & biotechnology2026
Repurposing antifungal drugs for Oral squamous cell carcinoma using network pharmacology, molecular docking and molecular dynamics approaches.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) remains an important cause of cancer morbidity and mortality, and new multi-target approaches are required to increase therapeutic options. Drug repurposing offers a promising strategy to identify new anticancer applications for clinically approved drugs with established safety profiles. An integrative in silico workflow was designed to identify overlapping targets between selected antifungal drugs and OSCC-associated genes based on network pharmacology and protein-protein interaction analysis. Network pharmacology identified 144 common targets for antifungals and OSCC, and EGFR and MMP9 were selected as druggable hubs based on their contributions to cancer progression. Molecular Docking revealed promising binding, with fluconazole (-8.5 kcal/mol) and itraconazole (-8.2 kcal/mol) showing better binding than the reference inhibitors tanomastat (-8.3) and erlotinib (-6.9) against MMP9 and EGFR, respectively. However, 200 ns molecular dynamics simulations and MM-PBSA calculations showed a different reality. Erlotinib and tanomastat showed the dynamic signature of specific binding, including persistent hydrogen bonds, restricted PCA clusters, and deep free energy minima. In contrast, fluconazole-EGFR showed thermodynamically unfavorable binding (+20.249 kJ/mol), fluconazole-MMP9 showed transient contacts mediated through zinc, and itraconazole-EGFR did not form persistent hydrogen bonds. Notably, the highest RMSD (0.31 ± 0.11 nm), protein destabilisation and unreliable binding energy (±101.005 kJ/mol) were shown by itraconazole-MMP9. The results imply that fluconazole and itraconazole are not specific and direct inhibitors of EGFR or MMP9, and their docking scores are artifacts from zinc chelation and hydrophobic overestimation. This study provides a cautionary computational framework emphasizing that rigorous MD and MM-PBSA validation is indispensable for reliable drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.